Education and Training
Adoptive Cell Therapy Long-term Follow-up (LTFU) Study
This trial will evaluate long term safety of participants who have received GlaxoSmithKline (GSK) adoptive cell therapy for up to 15 years following last adoptive cell therapy infusion.
Stanford is currently not accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- biological: GSK adoptive cell therapy
Eligibility
Inclusion Criteria:
- Participants who have received at least one dose of GSK adoptive cell therapy agent.
- Participants who have completed GSK sponsored or supported interventional study or
have withdrawn from it.
- Participants who have completed treatment as part of managed access to a GSK adoptive
cell therapy.
- Contraceptive use by men or women should be consistent with local regulations
regarding the methods of contraception for those participating in clinical studies.
- The investigator is responsible for review of medical history.
- Capable of giving signed informed consent.
Exclusion Criteria:
- None
Ages Eligible for Study
N/A - N/A
Genders Eligible for Study
All
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Ileana Aguilar Torres
650-724-1388
Not Recruiting